Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pharmascience Inc.
Canada’s Federal Court of Appeal has dismissed an attempt by Pfizer to limit damages owed to Pharmascience as part of litigation over pregabalin. The court rejected Pfizer’s argument that the generics firm was not entitled to certain damages for lost sales that Pfizer said could have been blocked by the originator hypothetically seeking to enforce a patent protecting the Lyrica brand.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.
Some believe unmet need refers only to rare diseases and tiny patient populations. But it is more than this. In 2020, the term sits at the heart of decision-making for drug makers – along with cost, access and value, of course.
From the general to the particular: drug developers are increasingly tailoring therapies to individuals. Driven by important advances in understanding biology as well as new tools to harness big data, industry participants expect significant progress in biopharma’s approach to the patient.
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
- PendoPharm, Rivex Pharma